3rd LNP Characterization & Analytical Development Summit
De-Risk Regulatory Submissions Through Smarter LNP Characterization

Curated in collaboration with leading analytical scientists and key LNP stakeholders, the 3rd LNP Characterization & Analytical Development Summit returns with new data, fresh insights, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization, this summit is your go-to platform for driving the development of safe, effective, and high-quality LNP-based drug products.

This highly focused, three-day agenda will equip analytical experts with the technical insights needed to:

• Accelerate development timelines
• Bridge critical analytical gaps
• Streamline regulatory submissions for faster approval

Join over 90 industry leaders in analytics, characterization, assays, and CMC from organizations including Pfizer, Novo Nordisk, Prime Medicine, Tessera Therapeutics, GSK, Sanofi, and more.

Key Benefits of Attending:

• Gain deep technical knowledge on cutting-edge LNP analytics
• Discover strategies to overcome common characterization challenges
• Align on regulatory expectations to support faster, smoother submissions
• Network with peers tackling the same development and regulatory hurdles

With data-driven presentations and expert-led discussions, this is your opportunity to help define and implement robust analytical strategies that support the rapid development and approval of next-generation genomic medicines.

Learn more here: https://ter.li/ympfix